Enliven Therapeutics (ELVN) Change in Acquisitions & Divestments (2020 - 2026)

Enliven Therapeutics has disclosed Change in Acquisitions & Divestments across 7 years of filings, most recently posting $108.4 million for Q1 2026.

• Change in Acquisitions & Divestments for Q1 2026 came in at $108.4 million, up 78.6% year-over-year; the trailing twelve-month figure through Mar 2026 was $320.6 million (down 4.49% YoY), and the FY2025 annual result was $272.9 million, down 13.07% from the prior year.
• Change in Acquisitions & Divestments came in at $108.4 million for Q1 2026 at Enliven Therapeutics, up from $87.7 million in the prior quarter.
• In the past five years, Change in Acquisitions & Divestments ranged from a high of $117.2 million in Q4 2024 to a low of -$12.0 million in Q3 2022.
• The 5-year median for Change in Acquisitions & Divestments is $64.2 million (2025), against an average of $58.2 million.
• Across the five-year window, Change in Acquisitions & Divestments plunged 189.2% in 2022 and soared 434.64% in 2023, its largest moves.
• Enliven Therapeutics' Change in Acquisitions & Divestments stood at -$12.0 million in 2022, then jumped by 769.29% to $80.0 million in 2023, then soared by 46.55% to $117.2 million in 2024, then decreased by 25.21% to $87.7 million in 2025, then climbed by 23.58% to $108.4 million in 2026.
• The last three Change in Acquisitions & Divestments figures came in at $108.4 million (Q1 2026), $87.7 million (Q4 2025), and $67.8 million (Q3 2025), per Business Quant data.